The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC).
Fatima H. Karzai
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Yangmin M. Ning
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
Philip M. Arlen
No relevant relationships to disclose
Melony A. Beatson
No relevant relationships to disclose
Nancy Harold
No relevant relationships to disclose
Anna Couvillon
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Clara Chen
No relevant relationships to disclose
Nancy Ann Dawson
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose